-
1
Lytenava approved for ophthalmic use, priced at £470 per injection.
-
2
Bevacizumab used off-label for retinal diseases due to cost-effectiveness.
-
3
Proposed sustainable price for bevacizumab: €73 to €
-
4
Manufacturing costs and patient populations largely determine prices.
-
5
Current pricing dynamics affect investment in drug development.
-
6
Transparency in cost structures can facilitate better pricing discussions.
-
7
Unique challenges exist for repurposed drugs in maintaining affordability.
Original Source(s)
Related Content
The European Myopia Network
A collaborative platform for myopia experts in Europe
March 20, 2026
-
7 min
Expanding the Therapeutic Landscape in Wet Age-related Macular Degeneration
The role of TKIs and sustained‑release delivery
March 20, 2026
-
6 min
Ophthalmology’s Role in the Opioid Crisis
Retrospective cohort study investigates how ophthalmologists can provide potentially life-saving care to substance use disorder patients
by Alun Evans
March 19, 2026
-
5 min
